newsfilter
← Latest News
GlobeNewswire·

Satsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing; key trial on track to read out topline results in Q4 2022 - - $95.8 million in cash, cash equivalents and marketable securities as of December 31, 2021, provides runway into second half of 202